Abstract: Presented herein, in certain aspects, are methods of preventing, reducing, delaying and treating Post-Intensive Care Cognitive Dysfunction (PICCD) by administering a compound disclosed herein to a subject prior to, during and/or after a stay in an ICU, intubation or connection to a ventilator. Also presented herein, in certain aspects, are methods of treating, preventing, inhibiting, reducing the severity of, or delaying the onset of a cognitive impairment or a cognitive disorder resulting from, or caused by respiratory distress.

Abstract: Embodiments disclosed herein relate to certain compositions including X-ray contrast media compounds and/or certain tri-iodinated phenyl compounds and methods of using the same for preventing or treating filovirus infections.

Abstract: Compounds that inhibit the peptidyl-prolyl isomerase (rotamase) enzyme activity of the FK-506 binding protein (FKBP) and compositions comprising these compounds are described. The FKBP-inhibiting compounds have a bicyclic [3.3.1], [4.3.1] or polycyclic azaamide nucleus. Pharmaceutical compositions containing such compounds help stimulate the outgrowth of neurites in nerve cells and augmenting nerve regeneration. Methods of treating nerve cells with such compositions are useful to promote repair of neuronal damage caused by disease and physical trauma.

Abstract: The identification, isolation and modification of human ERAB or HADH2 is described. A crystal structure of ERAB or HADH2 is described which may be used in the discovery, identification and characterization of inhibitors or modulators of ERAB or HADH2. This structure provides a three-dimensional description of binding sites of ERAB or HADH2 for structure-based design of inhibitors or modulators thereof as therapeutic agents, for example in the treatment of Alzheimer's disease).